Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
R Dhanasekaran, A Deutzmann… - Nature reviews Clinical …, 2022 - nature.com
The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …
Targeting STAT3 in cancer immunotherapy
S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Targeting the epigenetic regulation of antitumour immunity
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …
cancer onset and progression. Although defective gene regulation often affects oncogenic …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
DE Johnson, RA O'Keefe, JR Grandis - Nature reviews Clinical …, 2018 - nature.com
Abstract The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer,
and such hyperactivation is generally associated with a poor clinical prognosis. In the …
and such hyperactivation is generally associated with a poor clinical prognosis. In the …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Tumor cells form immune escape and subsequently obtain unlimited proliferation ability due
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
to the abnormal immune surveillance mediated by immune checkpoints. Among this class of …
[HTML][HTML] The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Q Lin, X Wang, Y Hu - Cancer Letters, 2023 - Elsevier
The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …